Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
CYTK Analyst Ratings
Strong Buy
15 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CYTK Stock 12 Month Forecast
Average Price Target
$81.43
▲(86.64% Upside)
| Highest Price Target$120.00 | Average Price Target$81.43 | Lowest Price Target$62.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
Reiterated
03/18/25
RBC Capital
Reiterated
03/10/25
Citi
Reiterated
03/10/25
Morgan Stanley
Reiterated
03/10/25
JMP Securities
Reiterated
03/10/25
Truist Financial
Reiterated
03/06/25
Mizuho Securities
Reiterated
03/06/25
B.Riley Financial
Reiterated
03/05/25
Needham
Reiterated
03/03/25
Leerink Partners
Reiterated
03/03/25
Evercore ISI
$65
Buy
48.98%
Upside
Reiterated
02/28/25
Analysts Conflicted on These Healthcare Names: Cytokinetics (NASDAQ: CYTK), Warby Parker (NYSE: WRBY) and 89bio (NASDAQ: ETNB)
Oppenheimer
$98→$96
Buy
120.03%
Upside
Reiterated
02/28/25
Cytokinetics (CYTK) PT Lowered to $96 at OppenheimerOppenheimer analyst Justin Kim lowered the price target on Cytokinetics (NASDAQ: CYTK) to $96.00 (from $98.00) while maintaining a Outperform rating.
Stifel Nicolaus
$80
Buy
83.36%
Upside
Reiterated
02/28/25
Stifel Nicolaus Remains a Buy on Cytokinetics (CYTK)
Piper Sandler
$107
Buy
145.24%
Upside
Reiterated
02/28/25
Cytokinetics (CYTK) Gets a Buy from Piper Sandler
Bank of America Securities
$62
Hold
42.10%
Upside
Reiterated
02/27/25
Cytokinetics' Mixed Outlook: Hold Rating Amid Execution Challenges and Modest Trial ImpactWe don’t disagree with bulls there are reasons to like the set-up, with the market still underpenetrated. But likely lost in the discussion over competitive dynamics, execution is unlikely to be straightforward, particularly given the logistical challenges administering CMIs. And with much to sort out from the company’s lack of an established footprint/ experience, we see just as many reasons to be cautious. With shares, in our view, fairly-valued, reiterate Neutral, $62 PO. How much of a delta in echo frequency is differentiating? Unsurprisingly, much of the discussion centered on afi’s REMS, which Cytokinetics has long maintained can be a key differentiator vs. Bristol’s Camzyos. Although afi’s mid- cycle review with FDA is set to take place in March, management reiterated its belief the monitoring requirements will be less.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
Reiterated
03/18/25
RBC Capital
Reiterated
03/10/25
Citi
Reiterated
03/10/25
Morgan Stanley
Reiterated
03/10/25
JMP Securities
Reiterated
03/10/25
Truist Financial
Reiterated
03/06/25
Mizuho Securities
Reiterated
03/06/25
B.Riley Financial
Reiterated
03/05/25
Needham
Reiterated
03/03/25
Leerink Partners
Reiterated
03/03/25
Evercore ISI
$65
Buy
48.98%
Upside
Reiterated
02/28/25
Analysts Conflicted on These Healthcare Names: Cytokinetics (NASDAQ: CYTK), Warby Parker (NYSE: WRBY) and 89bio (NASDAQ: ETNB)
Oppenheimer
$98→$96
Buy
120.03%
Upside
Reiterated
02/28/25
Cytokinetics (CYTK) PT Lowered to $96 at OppenheimerOppenheimer analyst Justin Kim lowered the price target on Cytokinetics (NASDAQ: CYTK) to $96.00 (from $98.00) while maintaining a Outperform rating.
Stifel Nicolaus
$80
Buy
83.36%
Upside
Reiterated
02/28/25
Stifel Nicolaus Remains a Buy on Cytokinetics (CYTK)
Piper Sandler
$107
Buy
145.24%
Upside
Reiterated
02/28/25
Cytokinetics (CYTK) Gets a Buy from Piper Sandler
Bank of America Securities
$62
Hold
42.10%
Upside
Reiterated
02/27/25
Cytokinetics' Mixed Outlook: Hold Rating Amid Execution Challenges and Modest Trial ImpactWe don’t disagree with bulls there are reasons to like the set-up, with the market still underpenetrated. But likely lost in the discussion over competitive dynamics, execution is unlikely to be straightforward, particularly given the logistical challenges administering CMIs. And with much to sort out from the company’s lack of an established footprint/ experience, we see just as many reasons to be cautious. With shares, in our view, fairly-valued, reiterate Neutral, $62 PO. How much of a delta in echo frequency is differentiating? Unsurprisingly, much of the discussion centered on afi’s REMS, which Cytokinetics has long maintained can be a key differentiator vs. Bristol’s Camzyos. Although afi’s mid- cycle review with FDA is set to take place in March, management reiterated its belief the monitoring requirements will be less.
CYTK Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
21
18
18
27
31
Buy
21
18
14
10
9
Hold
12
7
7
4
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
54
43
39
41
43
Each month's total comprises the sum of three months' worth of ratings.
CYTK Financial Forecast
CYTK Stock Forecast FAQ
What is CYTK’s average 12-month price target, according to analysts?
Based on analyst ratings, Cytokinetics’s 12-month average price target is $81.43.
What is CYTK’s upside potential, based on the analysts’ average price target?
Cytokinetics has 86.64% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CYTK a Buy, Sell or Hold?
Cytokinetics has a consensus rating of Strong Buy which is based on 15 buy ratings, 1 hold ratings and 0 sell ratings.
What is Cytokinetics’s price target?
The average price target for Cytokinetics is $81.43. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $62.00. The average price target represents 86.64% Increase from the current price of $43.63.
The highest analyst price target is $120.00 ,the lowest forecast is $62.00. The average price target represents 86.64% Increase from the current price of $43.63.
What do analysts say about Cytokinetics?
Cytokinetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
How can I buy shares of CYTK?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.